drugset
drugset / Trial / NCT06916273

Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult Subjects

NCT06916273 ↗

Phase 1 Completed 40 enrolled Anhui Palo Alto Pharmaceuticals, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of Inhalation aerosol PA9159, to establish maximum tolerated dose in healthy chinese adult

Timeline

Start
2024-07-22
Primary completion
2024-09-12
Completion
2024-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject PA9159 Small molecule 60 ug Inhaled
Subject PA9159 Small molecule 120 ug Inhaled
Subject PA9159 Small molecule 240 ug Inhaled
Subject PA9159 Small molecule 300 ug Inhaled

Indications

asthma